Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Long-Term Deferred Tax for 9 years, with the latest figure at $193.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 6.98% year-over-year to $193.6 million; the trailing twelve-month figure through Mar 2026 stood at $193.6 million (down 6.98% YoY), and the FY2025 full-year result was $198.1 million, down 6.16% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $193.6 million, down from $198.1 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $219.3 million in Q4 2023, with the low at $184.4 million in Q1 2023.
• Historically, Long-Term Deferred Tax has averaged $201.2 million across 5 years, with a median of $203.9 million in 2023.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax increased 18.22% — and 2026, when it slipped 6.98%.
• Kiniksa Pharmaceuticals International's Long-Term Deferred Tax stood at $185.5 million in 2022, then climbed by 18.22% to $219.3 million in 2023, then declined by 3.71% to $211.2 million in 2024, then decreased by 6.16% to $198.1 million in 2025, then fell by 2.28% to $193.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $193.6 million (Q1 2026), $198.1 million (Q4 2025), and $201.3 million (Q3 2025), per Business Quant data.